Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) frequently coexist due to shared risk factors. Their rising prevalence parallels the growing epidemic of obesity and insulin resistance (IR). In patients with T2DM and biopsy-proven NAFLD, a significantly higher prevalence of nonalcoholic steatohepatitis (NASH) (63-87%), any fibrosis (22-60%), and advanced fibrosis (4-9%) is noted. Possible risk factors for more advanced liver disease include concomitant metabolic syndrome with three or more components, visceral obesity, older age, increased duration of diabetes, and family history of diabetes. Liver biopsy is strongly suggested in these patients. Cardiovascular disease (CVD) and malignancy are the leading causes of death in this population, but a growing body of evidence shows liver-related mortality as an important cause of death, including an increased rate of hepatocellular carcinoma (HCC) in diabetes. The presence of NAFLD in T2DM is also associated with increased overall mortality. We aim with this review to summarize the results from studies investigating NAFLD in T2DM and to outline the factors that predict more advanced liver histology as well as the impact of these hepatic changes on CVD, overall and liver-related mortality.

[1]  I. Kamel,et al.  Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study , 2011, BMJ : British Medical Journal.

[2]  M. Arrese,et al.  Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass , 2005, Obesity surgery.

[3]  R. de Marco,et al.  Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. , 1999, Diabetes care.

[4]  J. Machan,et al.  Nonalcoholic Fatty Liver Disease in Severely Obese Subjects , 2007, The American Journal of Gastroenterology.

[5]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[6]  N. Patel,et al.  Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. , 2006, Annals of hepatology.

[7]  T. Trainer,et al.  Prevalence of Non-alcoholic Steatohepatitis in Morbidly Obese Subjects Undergoing Gastric Bypass , 2003, Obesity surgery.

[8]  D. Amarapurkar,et al.  Non‐alcoholic steatohepatitis in type 2 diabetes mellitus , 2004, Journal of gastroenterology and hepatology.

[9]  Z. Younossi,et al.  Nonalcoholic fatty liver disease in patients with type 2 diabetes. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[11]  M. Abraham,et al.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.

[12]  G. Targher,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[13]  R. Stravitz,et al.  Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome , 2003, American Journal of Gastroenterology.

[14]  E. Brunt,et al.  Diabetic hepatosclerosis: a 10‐year autopsy series , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[15]  A. Sanyal.  Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[16]  B. Fyfe,et al.  Diabetic microangiopathy in the liver: an autopsy study of incidence and association with other diabetic complications. , 2009, American journal of clinical pathology.

[17]  L. N. Valenti,et al.  Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[18]  L. Adams,et al.  Non-alcoholic fatty liver disease , 2011, Critical reviews in clinical laboratory sciences.

[19]  Z. Goodman,et al.  Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients , 2005, Obesity surgery.

[20]  K. Lindor,et al.  Nonalcoholic fatty liver disease , 2005, Canadian Medical Association Journal.

[21]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[22]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[23]  S. Harrison,et al.  Cardiovascular Disease and Nonalcoholic Fatty Liver Disease: Does Histologic Severity Matter? , 2012, Journal of clinical gastroenterology.

[24]  C. Byrne.  Dorothy Hodgkin Lecture 2012 * Non‐alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[25]  O. Cummings,et al.  Glycogenic Hepatopathy: An Underrecognized Hepatic Complication of Diabetes Mellitus , 2006, The American journal of surgical pathology.

[26]  V. Pannain,et al.  Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[27]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[28]  A. Sanyal.  NASH: A global health problem , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[29]  Joshi,et al.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. , 2009, The Journal of the Association of Physicians of India.

[30]  R. Lencioni,et al.  The etiology of hepatocellular carcinoma and consequences for treatment. , 2010, The oncologist.

[31]  S. Schneider,et al.  Clinical resolution of glycogenic hepatopathy following improved glycemic control. , 2008, Journal of diabetes and its complications.

[32]  P. Hayes,et al.  Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study , 2011, Diabetes Care.

[33]  Scott Harmsen,et al.  Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study , 2010, The American Journal of Gastroenterology.

[34]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[35]  L. N. Valenti,et al.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes , 2008, Hepatology.

[36]  K. Chayama,et al.  Postprandial insulin secretion pattern is associated with histological severity in non‐alcoholic fatty liver disease patients without prior known diabetes mellitus , 2011, Journal of gastroenterology and hepatology.

[37]  M. Manns,et al.  Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C , 2003, Hepatology.

[38]  J. Silverman,et al.  Liver pathology in morbidly obese patients with and without diabetes. , 1990, The American journal of gastroenterology.

[39]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[40]  P. Bejarano.  Does Nonalcoholic Fatty Liver Disease Predispose Patients to Hepatocellular Carcinoma in the Absence of Cirrhosis , 2010 .

[41]  D. Flum,et al.  Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. , 2003, Archives of surgery.

[42]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[43]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[44]  G. Pacini,et al.  Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients , 2001, Lipids.

[45]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[46]  J. George,et al.  Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis , 2006, Hepatology.

[47]  V. H. Rios Leite,et al.  Hepatic Histopathology of Patients with Morbid Obesity Submitted to Gastric Bypass , 2005 .

[48]  H. El‐Serag,et al.  Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.

[49]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[50]  A. Zanella,et al.  Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.

[51]  Jian-Gao Fan,et al.  [Clinical and histological features of non-alcoholic fatty liver disease]. , 2009, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[52]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[53]  L. Fernández-Salazar,et al.  Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. , 2004, Diabetes care.

[54]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[55]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[56]  F. Chan,et al.  Clinical and histological features of non‐alcoholic fatty liver disease in Hong Kong Chinese , 2004, Alimentary pharmacology & therapeutics.

[57]  K. Nouso,et al.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. , 2010, World journal of gastroenterology.

[58]  F. Negro,et al.  The interaction of metabolic factors with HCV infection: does it matter? , 2012, Journal of hepatology.

[59]  R. Xu,et al.  Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study , 2008, The American Journal of Gastroenterology.

[60]  G. Bedogni,et al.  Epidemiology of Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[61]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[62]  Donghee Kim,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease , 2014 .

[63]  Z. Goodman,et al.  Diabetic hepatosclerosis: diabetic microangiopathy of the liver. , 2006, Archives of pathology & laboratory medicine.

[64]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[65]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[66]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[67]  L. Kuller,et al.  Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. , 2003, American journal of physiology. Endocrinology and metabolism.

[68]  R. Marlar.  Are the laboratory results (phenotype) indicative of a true genotype abnormality? , 2012, American journal of clinical pathology.

[69]  J. Hoofnagle,et al.  Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. , 1988, Gastroenterology.

[70]  G. Targher,et al.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.

[71]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[72]  K. McGlynn,et al.  LIVER Diabetes increases the risk of hepatocellular carcinoma in the United States : a population based case control study , 2005 .

[73]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[74]  J. Ertle,et al.  Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis , 2011, International journal of cancer.

[75]  G. Zoppini,et al.  Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study , 2005, Alimentary pharmacology & therapeutics.

[76]  H. Lamb,et al.  Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. , 2010, Journal of the American College of Cardiology.